Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has unveiled clinical trial data for a KRAS-targeting drug combination aimed at treating metastatic pancreatic cancer.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Revolution Medicines is reporting Phase 1/2 clinical results for a combination regimen involving Zoldonrasib and Daraxonrasib. The treatment is being studied for its application in patients diagnosed with RAS G12D metastatic pancreatic cancer.
Coverage from outlets including Oncodaily, Medscape, Yahoo Finance, WSAW, and Endpoints News highlights the presentation of this data at the ESMO Gastrointestinal Cancers Congress 2026. The information is being characterized by some sources as potentially practice-changing for gastrointestinal oncology.
Future developments will depend on further clinical evaluation of the drug combination in second and third-line settings. Coverage does not yet specify the long-term trial schedule or regulatory timelines.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What drugs are included in the study?
The combination regimen consists of Zoldonrasib and Daraxonrasib.
Where were these findings presented?
The data was presented at the ESMO Gastrointestinal Cancers Congress 2026.
Which cancer types are being targeted?
The trial focuses on patients with RAS G12D metastatic pancreatic cancer.
Coverage (5)
- Anirban Maitra։ Data on Zoldonrasib Plus Daraxonrasib in 2nd and 3rd Line Metastatic Pancreatic Cancer Oncodaily · 1d ago
- Practice-Changing Data in GI Oncology Medscape · 1d ago
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Yahoo Finance · 1d ago
- Experimental cancer drug brings time and hope for patients WSAW · 1d ago
- Revolution Medicines shares promising data around KRAS drug combination Endpoints News · 1d ago
Topics
Related trends
Drug Stops 90% of Pancreatic Cancer Migration in Lab Tests
Recent laboratory findings indicate a drug may impede 90% of pancreatic cancer cell migration and trigger self-destruction.
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS lung-cancer drug candidate has outperformed existing therapies in a late-stage clinical trial.
Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope
Experimental drug daraxonrasib is drawing attention for its performance in clinical trials targeting advanced pancreatic cancer.